Partner Relations

Founded in 2010, the ATA Corporate Leadership Council (CLC) provides a unique and valuable forum for open communication between the ATA and the community of corporations that share interest in thyroid health and biology.
2017 ATA Corporate Leadership Council Meeting – The next CLC meeting will be held during the 87th Annual Meeting of the American Thyroid Association in Victoria, BC, Canada. For information on CLC membership and the CLC Meeting, please email khoff@thyroid.org.

The ATA has created and made available at its web site this complete Institutional Conflict of Interest Disclosure, which will be updated annually.

Annual CLC Partnership

Abbott India

www.abbott.co.in

Abbott India Limited (AIL) is one of India’s fastest growing pharmaceutical businesses. Headquartered in Mumbai, Abbott India Limited, is a publicly listed company (BSE: ABBOT) and a subsidiary of Abbott Laboratories, USA. The Company enjoys a leading presence in multiple therapeutic categories including Women’s Health, Gastroenterology, Neuro-psychiatry, Thyroid management and Liver health. Its success is driven by a combination of a highly competent and motivated team, R&D backed products, and strong alliances and partnerships with its suppliers and customers. Abbott India Limited reaches customers through a network of 25 distribution points which cater to over 5,200 stockists and 150,000 retail outlets. Visit us at: http://www.abbott.co.in

AbbVie

www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Eisai, Inc.

www.eisai.com/US

100 Tice Boulevard

Woodcliff Lake, NJ 07677

As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Exelixis, Inc.

www.exelixis.com

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

Genzyme Corporation

www.genzyme.com

500 Kendall Street

Cambridge, MA 02142

Phone: (617) 252-7500

Genzyme, a Sanofi company, has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Visit www.genzyme.com.

Quest Diagnostics

Quest Diagnostics offers comprehensive, integrated and innovative Thyroid Cancer Testing Solutions to provide you with the diagnostic insights you need to effectively diagnose and treat your patients. With nearly 800 M.D. and Ph.D level professionals we are a leader in the medical laboratory industry. We provide a comprehensive diagnostic portfolio for Thyroid Cancer, from screening and diagnosis to prognosis, treatment selection and monitoring. Our consultative network for Thyroid Pathology is comprised of board-certified pathologists with extensive experience in Thyroid Cancer. Find out more at www.QuestDiagnostics.com

Rosetta Genomics

Our mission is to leverage our diagnostics to offer clinically relevant testing solutions through our RosettaGX™ platform of tests. Our tests decipher genomic information and reveal actionable results to help solve unmet clinical needs. We’re focused on clarifying the pathway to personalized, precision medicine by enabling physicians to select the most appropriate treatment path for their patients.

Mary Ann Liebert, Inc. Publishers

www.liebertpub.com

140 Huguenot Street, 3rd Floor

New Rochelle, NY 10801

Phone: (914) 740-2100

Mary Ann Liebert, Inc. publishes authoritative peer-reviewed journals in promising areas of science and biomedical research, including Thyroid, the Official Journal of the American Thyroid Association. Thyroid (www.liebertpub.com/thy), published in print and online monthly, is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated ATA Guidelines for Managing Thyroid Disease.

Veracyte

www.veracyte.com

6000 Shoreline Court, Suite 300

South San Francisco, CA 94080

Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Spectrix Therapeutics, LLC
www.Spectrixtx.com

1256 Main Street, Ste 249
Southlake, TX 76092

Spectrix Therapeutics, LLC is a privately-held specialty pharmaceutical company committed to transforming how metabolic and endocrine disorders are treated pharmacologically. Through application of our proprietary multi-particulate drug delivery technologies we are able to provide tailored drug profiles to achieve optimal therapeutic effect, thereby enriching patient quality of life and further fueling the progress of medicine.